Individual studies and pilot trials of pentoxifylline in nonalcoholic steatohepatitis have suggested that anti-inflammatory therapy had effectively biochemical improvement and cytokine-mediated systemic inflammation amelioration (i.e., reduced plasma TNF-α and IL-6 levels). Here, TNF is linked to metabolic dysfunction-associated steatohepatitis.